Structure-activity relationships of bioisosteres of a carboxylic acid in a novel class of bacterial translation inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 14, 2007, Pages 4040-4043

  Ruble, J Craig ^a   Wakefield, Brian D ^a   Kamilar, Gregg M ^a   Marotti, Keith R ^a   Melchior, Earline ^a   Sweeney, Michael T ^a   Zurenko, Gary E ^a   Romero, Donna L ^a  

^a PFIZER INC   (United States)

Author keywords

Antibacterial; Bioisostere; Carboxylic acid; Protein binding; Translation inhibitor

Indexed keywords

ANTHRANILIC ACID DERIVATIVE; ANTIINFECTIVE AGENT; BIOISOSTERE; CARBOXYLIC ACID DERIVATIVE; FUNCTIONAL GROUP; NOVOBIOCIN; PROTON; TRANSLATION INHIBITOR; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRUCTURE ACTIVITY RELATION; TRANSLATION REGULATION;

BACTERIA; CARBOXYLIC ACIDS; MICROBIAL SENSITIVITY TESTS; PROTEIN BIOSYNTHESIS; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS);

EID: 34250360178     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.04.074     Document Type: Article

References (17)

1. Cohen M.L. Science 257 (1992) 1050
2. Allen N.E. In: Ellis G.P., and Luscombe D.K. (Eds). Progress in Medicinal Chemistry Vol. 32 (1995), Elsevier Science, New York 157 Chapter 4
3. Hayes J.D., and Wolf C.R. Biochem. J. 272 (1990) 281
4. Spratt B.G. Science 264 (1994) 388
5. Nikaido H. Science 264 (1994) 382
6. Russell A.D. In: Ellis G.P., Luscombe D.K., and Oxford A.W. (Eds). Progress in Medicinal Chemistry Vol. 35 (1998), Elsevier Science, New York Chapter 4
7. Fuchs T.M. Naturwissenschaften 85 (1998) 99
8. Cunha B.A. Drugs Today 34 (1998) 691
9. Larsen S.D., Hester M.R., Ruble J.C., Kamilar G.M., Romero D.L., Wakefield B., Melchior E.P., Sweeney M.T., and Marotti K.R. Bioorg. Med. Chem. Lett. 16 (2006) 6173
10. Li J., Wakefield B.D., Ruble J.C., Stiff C.M., Romero D.L., Marotti K.R., Sweeney M.T., Zurenko G.E., Rohrer D.C., and Thorarensen A. Bioorg. Med. Chem. Lett. 17 (2007) 2347
11. Thorarensen A., Wakefield B.D., Romero D.L., Marotti K.R., Sweeney M.T., Zurenko G.E., Rohrer D.C., Han F., and Bryant G.L. Bioorg. Med. Chem. Lett. 17 (2007) 2823
12. Peters Jr. T. All About Albumin: Biochemistry, Genetics, and Medical Applications (1996), Academic Press, New York
13. Murray R.W., Melchior E.P., Hagadorn J.C., and Marotti K.R. Antimicrob. Agents Chemother. 45 (2001) 1900
14. a predictor was used for these calculations: http://www.acdlabs.com/.
15. Chen X., and Wang W. The Use of Bioisosteric Groups in Lead Optimization. In: Doherty A. (Ed). Annual Reports in Medicinal Chemistry Vol. 38 (2003), Elsevier 333-346
16. Wermuth C.G. Molecular Variations Based on Isosteric Replacements. In: Wermerth C. (Ed). Practice of Medicinal Chemistry (2003), Academic Press 189-214
17. The lack of correlation of T/T activity with antibacterial activity as well as previous reports of 1,1,1,3,3,3-hexafluoro-2-phenyl-2-propanol serving as an antibacterial agent suggest that compound 33 may act via a different mechanism, see:. Sidorenko S.S., Aizenberg S.Z., Blakitnyi A.N., Fialkov Y.A., and Yagupol'skii L.M. Fiziologicheski Aktivnye Veshchestva 4 (1972) 41